Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF; Drug: UMEC; Drug: VI
Sponsor: GlaxoSmithKline
Not yet recruiting – verified May 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668); Drug: fluticasone propionate and salmeterol; Drug: budesonide and formoterol; Drug: mometasone furoate and formoterol
Sponsors: Sanofi; Regeneron Pharmaceuticals
Not yet recruiting – verified May 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Condition: Nasal Polyps
Interventions: Drug: dupilumab SAR231893 (REGN668); Other: placebo; Drug: mometasone furoate nasal spray
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Not yet recruiting – verified August 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext
Condition: Handling of Auto-injectors
Intervention: Drug: Adrenaline auto-injector
Sponsors: ALK Nordic A/S, Danmark Filial; ALK Nordic A/S, Danmark Filial
Completed – verified June 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Not yet recruiting – verified March 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Diagnosis, evaluation and monitoring of asthma.
Diagnosis, evaluation and monitoring of asthma.
Allergol Int. 2012 Sep;61(3):351-2
Authors: Tamaoki J, Saito H
PMID: 23082326 [PubMed – in process]
View full post on pubmed: asthma
Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals … – 7thSpace Interactive (press release)
|
Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals …
7thSpace Interactive (press release) Despite the availability of effective therapies, asthma remains a source of significant morbidity and use of health care resources. The central research question of the ACCURATE trial is whether maximal doses of (combination) therapy should be used for … |
View full post on asthma – Google News
Evaluation of genetic susceptibility to childhood allergy and asthma in an … – 7thSpace Interactive (press release)
|
Evaluation of genetic susceptibility to childhood allergy and asthma in an …
7thSpace Interactive (press release) Asthma and allergy represent complex phenotypes, which disproportionately burden ethnic minorities in the United States. Strong evidence for genomic factors … |
View full post on asthma – Google News
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II
Condition: Asthma
Interventions: Drug: 50 mcg salmeterol HFA MDI; Drug: placebo; Drug: 5 mcg tiotropium Respimat®; Drug: 2.5 mcg tiotropium Respimat®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days